Transglutaminase Autoantibodies in Dermatitis Herpetiformis and Celiac Sprue  by Marietta, Eric V. et al.
Transglutaminase Autoantibodies in Dermatitis
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Joseph A. Murray4
Dermatitis herpetiformis (DH) is an autoimmune blistering skin disorder that is associated with intestinal gluten
sensitivity. Epidermal transglutaminase (TGe) and closely related tissue transglutaminase (tTG) are considered to
be autoantigens in DH, because a majority of DH patients have IgA specific for TGe and for tTG. It is unknown
where and how these autoantigen-specific IgAs are generated in DH. Results reported in this paper on nine DH
patients on a gluten containing diet demonstrate that the levels of circulating anti-tTG IgA and anti-TGe IgA in
DH are correlated with each other and that both appear to be correlated with the degree (extent) of
enteropathy. An analysis of 15 untreated celiac sprue (CS) patients demonstrated that approximately 33% of CS
patients had elevated levels of anti-TGe IgA. These results would indicate that intestinal damage is associated
with the production of anti-tTG IgA and anti-TGe IgA in DH patients.
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INTRODUCTION
Dermatitis herpetiformis (DH) is an autoimmune, blistering,
intensely pruritic papulovesicular rash typically located on
the elbows, forearms, buttocks, knees, and scalp (Hall, 1992;
Fry, 2002). It is often associated with an enteropathy
characterized by villous atrophy and/or increased infiltration
of intraepithelial lymphocytes (Fry, 1995; Cooney et al.,
1977). The enteropathy and the rash are caused by the
ingestion of gluten, which is a group of storage proteins of
wheat, barely, and rye. Another gluten sensitive disease, celiac
sprue (CS), results from a potent inflammatory response to
gluten within the small intestine (Reunala, 1998). Additionally,
even though gluten is the exogenous antigen for both CS and
DH, these two diseases have characteristics of autoimmune
disorders. These characteristics include a tight association with
major histocompatibility complex II molecules (HLA-DQ2 and
HLA-DQ8) and the production of circulating autoantibodies
(Spurkland et al., 1997; Sollid, 2000).
In 1984, Chorelezki reported that autoantibodies directed
against endomysial tissue were present in both DH and CS
and could be used as a marker for both diseases (Chorzelski
et al., 1984). Subsequently, it was found that these
endomysium-binding autoantibodies were directed specifi-
cally against tissue transglutaminase (tTG) (Dieterich et al.,
1997; Dieterich et al., 1999; Porter et al., 1999). The
presence of circulating anti-tTG IgA is commonly used as a
screening tool for celiac disease (James, 2005). Anti-tTG IgA
antibodies are also diagnostic markers for enteropathy in DH
patients (Kumar et al., 2001). Thus, anti-tTG IgA is an
autoantibody that is found in both diseases.
Interestingly, DH patients with villous atrophy have high
levels of circulating anti-endomysial IgA (Volta et al., 1992).
Levels of circulating anti-tTG IgA and anti-endomysial IgA are
correlated with the absence or presence of enteropathy in CS
patients, suggesting that these antibodies are produced in the
setting of mucosal injury (Kotze et al., 2003; Rostami et al.,
2003). Yet another study demonstrated that IgA deposits and
tTG colocalize in the jejunal samples of celiac patients and
that this IgA was tTG specific based on binding studies of
eluted jejunal IgA (Korponay-Szabo et al., 2004).
In 2002, another autoantigen, epidermal transglutaminase
(TGe), was identified for DH (Sardy et al., 2002; Karpati,
2004). In the perilesional tissue of DH patients, the IgA
deposits at the dermal/epidermal junction were found to
colocalize with TGe in the papillary dermis and small vessels
(Karpati, 2004; Preisz et al., 2005). DH patients also had
circulating TGe-specific IgA that fell into two groups. One
antibody group bound to TGe exclusively, whereas the
second antibody group was crossreactive and bound to both
tTG and TGe. This second group was found in celiac patients
as well and had a lower avidity for TGe than the first group.
The level of circulating TGe-specific IgA was lower in DH
patients on a gluten-free diet. This suggests that anti-TGe IgA
is also dependent upon the continued intestinal exposure to
gluten in DH patients, similar to anti-tTG IgA in CS patients.
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It is of interest then, as to whether the levels of anti-TGe
IgA or anti-tTG IgA that are found in DH or CS patients are
related to the degree or extent of mucosal injury, such as
villous atrophy, as a result of intestinal exposure to gluten. To
determine whether there is a correlation between the levels of
circulating anti-TGe IgA and enteropathy/villous atrophy in
DH and CS patients, we compared the titers of anti-TGe IgA
and anti-tTG IgA with the presence and severity of villous
atrophy.
RESULTS
Characterization of DH and CS patients
Nine DH patients that had not been on a gluten-free diet
were evaluated for this study (Table 1). Duration of blistering
disease varied from less than 0.5 years to 9 years (Table 1).
Fifteen untreated celiac patients who had never developed a
pruritic rash were evaluated (Table 2).
Correlation between the levels of anti-TGe IgA and anti-tTG IgA
in DH and CS patients
The levels of anti-TGe IgA and anti-tTG IgA were highly
correlated in DH patients, with a Pearson’s coefficient,
r¼ 0.74. (Figure 1a). There was no significant correlation
between the two autoantibodies in the untreated celiac
patients (r¼0.286, Figure 1b).
Relationship between enteropathy and serology
Marsh Scores were determined from the histopathological
analysis of the duodenal biopsies of six of the nine DH
patients and all of the 15 celiac patients. The scores varied
from 0 to 3c (Tables 1 and 2). All biopsies were evaluated
using the Marsh system of scoring (Oberhuber, 2000).
With the DH patients, there was a significant correlation
between the levels of anti-TGe IgA and the degree of
enteropathy (r¼ 0.82) (Figure 2a). A significant correlation
was also found between the marsh scores and levels of anti-
tTG IgA (r¼0.7) (Figure 2b). There was no correlation
between the levels of anti-TGe IgA and the level of villous
atrophy in the celiac patients (Figure 2a). Anti-tTG IgA also
does not correlate with the degree of villous atrophy in CS
patients (Figure 2b). However, all 15 celiac patients had
elevated levels of anti-tTG IgA, thus supporting previous
reports that elevated levels of anti-tTG IgA do correlate with
the presence of enteropathy.
DISCUSSION
Several lines of evidence support TGe as a target for IgA
autoantibodies in DH. Sardy et al. (2002) demonstrated that
the IgA deposits in the perilesional skin of DH patients
colocalizes with TGe, that DH and CS patients had
circulating anti-TGe IgA in their blood, and that DH and CS
patients on a gluten-free diet had lower levels of anti-TGe IgA
than those that were not. One possible explanation for this is
that the enteropathic process leads to the production of
circulating anti-TGe IgA in both CS and DH patients.
Our results suggest a correlation among the extent of
enteropathy, anti-tTG IgA and anti-TGe IgA in DH patients.
Albeit, greater numbers of DH patients that are on a gluten
containing diet would be necessary for definite proof of this
correlation. This result would suggest that the production of
these antibodies occurs as a result of mucosal damage in the
intestine of DH patients. This would certainly fit the accepted
theory that all DH patients have some level of intestinal
immunopathological response to gluten that manifests as a
skin condition.
Another important conclusion to be made from these
results is that some celiac patients produce anti-TGe IgA,
which supports a previous finding (Sardy et al., 2002). The
production of this antibody in celiac patients, however, did
not appear to be correlated with severity of villous atrophy in
their intestine. Similarly, the production of anti-tTG IgA in
celiac patients did not correlate with the severity of
enteropathy, which would also support a previous finding
(Tursi et al., 2003). One contributing factor to this lack of
correlation between the production of anti-tTG and anti-TGe
antibodies and the severity of enteropathy may be the fact
that CS patients on a gluten-containing diet by definition have
Marsh scores of 3 or greater, whereas all levels of severity can
be present in DH patients on a gluten containing diet.
Overall, however, these results would indicate that the
Table 1. Evaluated DH patients
DH patient no. Age (years) Sex Disease duration (years)1 Marsh score Villous atrophy
1 48 F o0.5 NA ?
2 75 F o0.5 0 No
3 57 M 5 0 No
4 68 M 9 NA ?
5 70 F o0.5 3c Yes
6 65 F o0.5 NA ?
7 35 M o0.5 3b Yes
8 70 M o0.5 3b Yes
9 75 M 3 1 No
F, female; M, male; NA, not applicable.
1All DH patients had IgA deposits in perilesional tissue.
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Table 2. Evaluated CS patients
CS Patient no. Sex Age Disease duration (years) Marsh score Villous atrophy
1 M 13 0.5 3c Yes
2 F 71 0 3b Yes
3 F 64 0 3c Yes
4 M 58 0.5 3b Yes
5 F 48 0 3c Yes
6 F 32 0 3c Yes
7 F 64 0 3c Yes
8 F 37 0 3c Yes
9 F 40 0 3c Yes
10 F 58 0.5 3b Yes
11 M 65 0.25 3b Yes
12 M 39 0 3a Yes
13 F 50 0 3a Yes
14 F 61 0 3c Yes
15 M 52 0.25 3a Yes
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Figure 1. Correlation between anti-tTG IgA and anti-TGe IgA levels in the
sera of DH and CS patients on a normal gluten containing diet.OD values for
anti-TGe IgA were plotted along the y axis and corresponding anti-tTG IgA
values for each patient plotted along the x axis. All patients were on a normal
gluten-containing diet. Nine DH patients were evaluated (a) (Pearson’s








































Figure 2. Comparing Marsh Scores with the levels of anti-tTG IgA and
anti-TGe IgA in DH and CS patients. Marsh scores for each DH (m) and
each CS patient (E) were determined and plotted on the x axis. OD values
for the corresponding anti-TGe IgA level (a) and for the corresponding
anti-tTG IgA level (b) for each DH and each CS patient was plotted on the
y axis. All patients were on a normal gluten-containing diet. Trend lines
are provided for the DH patients (solid). For anti-TGe IgA in DH, r¼0.82,
for anti-tTG IgA in DH, r¼0.7. For anti-TGe IgA in CS, r¼ 0.21, for anti-tTG
IgA in CS, r¼ 0.35.
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concentration of both antibodies in CS patients is indepen-
dent of the degree of villous atrophy.
It is of great interest then, to understand how and why
these antibodies are generated in both DH patients and celiac
patients. Clearly, the consumption of gluten triggers symp-
toms in both diseases, but the mechanisms behind the
production of these specific autoantibodies still remains
enigmatic. It is possible that the catalyst(s) for the production
of anti-tTG IgA and anti-TGe IgA in DH is (are) located in the
intestine and is (are) associated with intestinal damage.
Future work should be devoted to better understanding what
these catalysts (beyond the ingestion of wheat) are. It would
also be crucial to determine if the production of these
transglutaminase-specific antibodies is necessary for the
development of autoimmune pathology in both the small
intestine and skin, or if they are they solely consequences of
pathology in the intestine.
MATERIALS AND METHODS
Case definition
DH was diagnosed based upon the presence of pruritic papulo-
vesicular lesions and the presence of granular IgA deposits in
perilesional skin. Celiac sprue was defined as significant villous
atrophy.
At least four endoscopic biopsies from distal duodenum were
formalin fixed and paraffin embedded. Sections (5mm) were stained
with hematoxylin and eosin and scored based on the Marsh system.
Detection of anti-TGe IgA and anti-tTg IgA
Anti human tTG ELISA kits (The Binding Site Inc., San Diego, CA)
and anti TGe ELISA kits (Alpco, Windham, NH) were used to
measure the level of anti-tTG IgA and anti-TGe IgA in the sera of
patients. All OD values were normalized by subtracting the value of
the negative control provided in the kit. This would mean that any
sample that had an OD value greater than the negative control was
positive for the antibody tested.
Statistical analysis
Pearson’s correlation coefficients were calculated using Microsoft
Excel. This study was conducted according to the Declaration of
Helsinki Principles and approved by the Mayo Foundation Institu-
tional Review Board. Also, patients had provided consent before the
study.
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